Patent ID: 11926636
Assignee: PFIZER INC.
Field: Organic fine chemistry (Chemistry)
Classification: CPC C  A | IPC C

Claim 0:
1. A method of treating abnormal cell growth in a mammal comprising administering to the mammal a therapeutically effective amount of the crystalline form of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiaza-cyclotetradecine-3-carbonitrile (lorlatinib) maleate hydrate, having a powder X-ray diffraction (PXRD) pattern comprising two or more peaks at 2q values selected from the group consisting of: 10.6, 12.7, 16.2, 18.5 and 27.8 ° 2q±0.2 °2q, wherein the abnormal cell growth is cancer mediated by anaplastic lymphoma kinase (ALK) or c-ros oncogene 1 receptor tyrosine kinase (ROS1).